Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.
Mor
Adam
A
Division of Rheumatology, Department of Medicine, New York University School of Medicine/Hospital for Joint Diseases, New York, New York, USA. mora01@med.nyu.edu
Bingham
Clifton O
CO
Bingham
Clifton
C
Barisoni
Laura
L
Lydon
Eileen
E
Belmont
H Michael
HM
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology; D001171:Arthritis, Juvenile / Q000150:complications* / Q000188:drug therapy; D018572:Disease-Free Survival; D000068800:Etanercept; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000276:immunology; D008181:Lupus Nephritis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000009:adverse effects* / Q000276:immunology; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D028761:Withholding Treatment
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept